ABSTRACT
Objectives Post Acute Sequelae of COVID-19 (PASC) is an important health concern after the COVID-19 pandemic. We aimed to investigate the prevalence of respiratory system disorders before and after the pandemic onset in individuals with and without PASC.
Methods We designed a case-control study was designed to investigate the prevalence of respiratory system-related diagnoses in adult, non-hospitalized PASC patients (cases) in 2019, 12 months before and 6 months after the PASC diagnosis compared to matched controls without PASC. Data was extracted from the Stockholm Region’s database warehouse (VAL).
Results Higher diagnostic rates for common respiratory illnesses were observed among PASC patients in 2019 and 12 months before PASC diagnosis, which then slightly decreased 6 months after PASC diagnosis. PASC patients showed more pre-pandemic respiratory diagnoses compared to controls: in 2019 they had higher incidence of acute upper respiratory tract infection (OR 2.47 for males, 2.22 for females), asthma (OR 1.76 (males), 1.95 (females)), and bronchitis (OR 2.15 (males), 2.71 (females)) compared to controls.
Conclusions This study highlights that individuals with PASC have a higher prevalence of respiratory disorders both before and after their COVID-19 diagnosis. Notably, asthma and other respiratory conditions were more common in PASC patients compared to matched controls. Our study demonstrates that individuals with asthma are more likely to develop PASC, even if asthma does not increase the severity of acute COVID-19. These findings underscore the need for further investigation into the underlying mechanisms connecting respiratory illnesses and PASC. Understanding the long-term consequences of COVID-19 in individuals with pre-existing conditions will be crucial for refining clinical management strategies and improving patients outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Region Stockholm FoUI-97300, Swedish Heart-lung foundation, and Swedish Research Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Swedish Ethical Review Authority gave Ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Previous results are now divided based on organ-specific diagnoses, with a current focus on respiratory diagnoses.
Data Availability
All data produced in the present work are contained in the manuscript
List of abbreviations
- PASC
- Post Acute Sequelae of COVID-19
- VAL
- Stockholm Regional Health Care Data Warehouse
- ICD-10
- International Classification of Diseases, 10th edition
- OR
- odds ratio
- CI
- confidence interval
